

AVANIR PHARMACEUTICALS

Form 8-K

August 13, 2004

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

**FORM 8-K
CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 13, 2004

AVANIR PHARMACEUTICALS

(Exact Name of Registrant as Specified in Charter)

California

001-15803

33-0314804

(State of Incorporation or
Organization)

(Commission File Number)

(I.R.S. Employer Identification
No.)

11388 Sorrento Valley Road, Suite 200, San Diego, California

92121

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 622-5200

NOT APPLICABLE

(Former Name or Former Address, if Changed Since Last Report)

Item 7. Financial Statements and Exhibits.

Exhibit

99.1 Press release, dated August 13, 2004

Item 12. Results of Operations and Financial Condition.

On August 13, 2004, AVANIR Pharmaceuticals issued a press release announcing its results of operations for the quarter ended June 30, 2004. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 13, 2004

AVANIR PHARMACEUTICALS

By: /s/Gregory P. Hanson, CMA
Gregory P. Hanson, CMA
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release, dated August 13, 2004